A review on Metronomic Chemotherapy for Non-Small Cell Lung Cancer

Abstract

Metronomic chemotherapy (MCT) is the rhythmic administration of low-dose cytotoxic drugs over an extended length of time with little to no drug-free intervals. MCT has an impact on the tumor milieu and tumor cells. The low-dose timetable, in specific, hinders endothelial cells' ability to repair themselves, which has an anti-angiogenesis impact. MCT causes immunological stimulation, which prompts the immune system to attack tumor cells. Anti-angiogenic medications also improve the effectiveness of MCT when used in conjunction with targeted treatment. The current analysis provides a summary of phase I, phase II, and phase III clinical trials examining the effectiveness, side effects, and method of action of MCT in patients with non-small cell lung cancer. (NSCLC). The potential of MCT in treating NSCLC has also been considered. According to the current study, MCT is an effective treatment for specific NSCLC patients with manageable systemic side effects and financial viability for public health.